Multitarget PPARγ Agonists as Innovative Modulators of the Metabolic Syndrome
Abstract
A multitarget pharmacologic approach could be advantageous for the therapy of metabolic multiple diseases, such as the metabolic syndrome, which is characterized by metabolic abnormalities associated with diabetes, obesity, hypertension, and increased cardiovascular risk. PPAR receptors play a critical role in metabolic disorders, affecting glucose and lipid metabolism. Drugs simultaneously targeting PPAR and other validated metabolic targets, represent a promising multitarget approach to combine antihyperglycemic, antihyperlipidemic, and antihypertensive effects. This review offers a survey of recently developed multitarget PPARγ agonists as antidiabetic and antihypertensive drugs.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PPARs within the brain may serve as important molecular targets of PFAS that can impact metabolic homeostasis.
“PPARs within the brain may serve as important molecular targets of PFAS that can impact metabolic homeostasis”
From A Critical Review and Meta-Analysis of Impacts of Per- and Polyfluorinated Substances on the Brain and Behavior (2022) · cites this paper as Ammazzalorso et al., 2019
The citation lists haven’t been fetched yet
References 84 · Cited by 39
- Authors
- Ammazzalorso, A., Maccallini, C., Amoia, P., & Amoroso, R.
- Affiliations
- University of Chieti-Pescara (IT)
- Corresponding author
- Maccallini, Cristina
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 173
- Pages
- 261-273
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2939900094
- Cited by
- 39
- References
- 84
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 4 · 2019: 4
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- PPARγ agonists, multi-target drugs, metabolic syndrome, antidiabetic drugs, antihypertensive drugs, hypolipidemic effect, glucose metabolism, lipid metabolism, obesity, cardiovascular risk
- MeSH terms
- Animals, Antihypertensive Agents, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Humans, Hypertension, Hypoglycemic Agents, Structure-Activity Relationship, Molecular Structure, Metabolic Syndrome, PPAR gamma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
